🚀 VC round data is live in beta, check it out!
Nykode Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Nykode Therapeutics and similar public comparables like Aldeyra Therapeutics, Cantargia, Verrica Pharmaceuticals, Sangamo Therapeutics and more.
Nykode Therapeutics Overview
About Nykode Therapeutics
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need. It operates in United States of America.
Founded
2006
HQ
Employees
139
Website
Sectors
Financials (LTM)
EV
$52M
Nykode Therapeutics Financials
Nykode Therapeutics reported last 12-month revenue of — and negative EBITDA of ($32M).
In the same LTM period, Nykode Therapeutics generated — in gross profit, ($32M) in EBITDA losses, and had net loss of ($25M).
Revenue (LTM)
Nykode Therapeutics P&L
In the most recent fiscal year, Nykode Therapeutics reported revenue of — and EBITDA of ($16M).
Nykode Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($32M) | XXX | ($16M) | XXX | XXX | XXX |
| Net Profit | ($25M) | XXX | ($12M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Nykode Therapeutics Stock Performance
Nykode Therapeutics has current market cap of $109M, and enterprise value of $52M.
Market Cap Evolution
Nykode Therapeutics' stock price is $0.34.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $52M | $109M | -0.7% | XXX | XXX | XXX | $-0.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNykode Therapeutics Valuation Multiples
Nykode Therapeutics trades at (1.6x) EV/EBITDA.
EV / Revenue (LTM)
Nykode Therapeutics Financial Valuation Multiples
As of April 19, 2026, Nykode Therapeutics has market cap of $109M and EV of $52M.
Equity research analysts estimate Nykode Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nykode Therapeutics has a P/E ratio of (4.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $109M | XXX | $109M | XXX | XXX | XXX |
| EV (current) | $52M | XXX | $52M | XXX | XXX | XXX |
| EV/EBITDA | (1.6x) | XXX | (3.3x) | XXX | XXX | XXX |
| EV/EBIT | (1.8x) | XXX | (1.8x) | XXX | XXX | XXX |
| P/E | (4.4x) | XXX | (8.9x) | XXX | XXX | XXX |
| EV/FCF | (3.0x) | XXX | (2.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Nykode Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Nykode Therapeutics Margins & Growth Rates
Nykode Therapeutics' revenue in the last fiscal year declined by (100%).
Nykode Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.2M for the same period.
Nykode Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Growth | (24%) | XXX | 119% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Nykode Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Nykode Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aldeyra Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cantargia | XXX | XXX | XXX | XXX | XXX | XXX |
| Verrica Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Sangamo Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Vistin Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nykode Therapeutics M&A Activity
Nykode Therapeutics acquired XXX companies to date.
Last acquisition by Nykode Therapeutics was on XXXXXXXX, XXXXX. Nykode Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Nykode Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNykode Therapeutics Investment Activity
Nykode Therapeutics invested in XXX companies to date.
Nykode Therapeutics made its latest investment on XXXXXXXX, XXXXX. Nykode Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Nykode Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Nykode Therapeutics
| When was Nykode Therapeutics founded? | Nykode Therapeutics was founded in 2006. |
| Where is Nykode Therapeutics headquartered? | Nykode Therapeutics is headquartered in Norway. |
| How many employees does Nykode Therapeutics have? | As of today, Nykode Therapeutics has over 139 employees. |
| Who is the CEO of Nykode Therapeutics? | Nykode Therapeutics' CEO is Michael Thyrring Engsig. |
| Is Nykode Therapeutics publicly listed? | Yes, Nykode Therapeutics is a public company listed on Oslo Børs. |
| What is the stock symbol of Nykode Therapeutics? | Nykode Therapeutics trades under NYKD ticker. |
| When did Nykode Therapeutics go public? | Nykode Therapeutics went public in 2020. |
| Who are competitors of Nykode Therapeutics? | Nykode Therapeutics main competitors are Aldeyra Therapeutics, Cantargia, Verrica Pharmaceuticals, Sangamo Therapeutics. |
| What is the current market cap of Nykode Therapeutics? | Nykode Therapeutics' current market cap is $109M. |
| Is Nykode Therapeutics profitable? | No, Nykode Therapeutics is not profitable. |
| What is the current EBITDA of Nykode Therapeutics? | Nykode Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Nykode Therapeutics? | Current EBITDA multiple of Nykode Therapeutics is (1.6x). |
| What is the current FCF of Nykode Therapeutics? | Nykode Therapeutics' last 12 months FCF is ($17M). |
| What is the current EV/FCF multiple of Nykode Therapeutics? | Current FCF multiple of Nykode Therapeutics is (3.0x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.